Epiomic Epidemiology Series: Idiopathic Pulmonary Fibrosis Forecast in 9 Major Markets 2015-2025

Date: 2015-12

Idiopathic pulmonary fibrosis (IPF) is defined as a specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause. The disease is idiopathic, although a number of possible causes have been identified, including exposure to various dusts and smoking. This report provides the current prevalent population for IPF across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report provides a breakdown of the course of the disease, progressive vs. stable, with the definite diagnosed IPF patient population. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of IPF have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for IPF include:
• Cardiovascular Disease
• Presence of clubbing
• Air ventilation assistance
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global IPF market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of IPF and identify patient segments with high potential. This would include patients diagnosed with definite or probable IPF.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on IPF’s prevalent population.
• Identify sub-populations within IPF which require treatment.
• Gain an understanding of the specific markets that have the largest number of IPF patients.


Contact With Us
Join templatemonster at google+
Customized Research
Request Sample